Additional Details
-
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Legacy Research InstitutePortland OR. 97232 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Loyola University Medical Center (LUMC)Maywood IL. 60153 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
The University of Texas Health San Antonio Medical Arts & Research CenterSan Antonio TX. 78229-3901 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Baylor College of MedicineHouston TX. 77030 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
University of Michigan Health SystemMichigan Center MI. 48109 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
University of Pittsburgh Medical CenterPittsburgh PA. 15213 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Tufts Medical CenterBoston MA. 02111 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Duke University Medical CenterDurham NC. 27705 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Dignity Health Norton Thoracic InstitutePhoenix AZ. 85013 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Lowcountry Lung and Critical CareCharleston SC. 29406 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Pulmonary Associates, PAMesa AZ. 85206-1346 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
The Lung Research Center, LLCChesterfield MO. 63017 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
University of Kansas Medical Center Research Institute, IncKansas City KS. 66160 -
FAPI PET for Lung Fibrosis
UCLA / Jonsson Comprehensive Cancer CenterLos Angeles CA. 90095 -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
University of ArizonaTucson AZ. 85724 -
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
University Health Network Toronto General HospitalToronto ON. M5G 2N2 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
UCLA Health Westwood Medical PlazaWestwood CA. 90095 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
National Jewish Health Medical Center ( Site 4015)Denver CO. 80206 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
University of Michigan Hospital ( Site 4001)Ann Arbor MI. 48109